Congenital Generalized Lipoatrophy (Berardinelli-Seip Syndrome) Type 1: Description of Novel AGPAT2 Homozygous Variants Showing the Highly Heterogeneous Presentation of the Disease

Por Giovanni Ceccarini, Silvia Magno, Caterina Pelosini, Caterina Pelosini, Federica Ferrari, Maria Rita Sessa, Gaia Scabia, Gaia Scabia, Margherita Maffei, Margherita Maffei, Isabelle Jéru, Isabelle Jéru, Olivier Lascols, Olivier Lascols, Corinne Vigouroux, Corinne Vigouroux, Corinne Vigouroux, Ferruccio Santini
Publicado em 2020-02-01

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

Por Black, Jonathan D, Lopez, Salvatore, Cocco, Emiliano, Bellone, Stefania, Altwerger, Gary, Schwab, Carlton L, English, Diana P, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Santin, Alessandro D
Publicado no Br J Cancer (2015)

Psychiatric disorder as clinical presentation of primary Sjögren's syndrome: two case reports

Por Pelizza, Lorenzo, Bonacini, Federica, Ferrari, Alberto
Publicado em 2010

Massive thymic hemorrhage and hemothorax occurring in utero

Por Gargano, Giancarlo, Paltrinieri, Anna Lucia, Gallo, Claudio, Di Pancrazio, Luciana, Roversi, Maria Federica, Ferrari, Fabrizio
Publicado no Ital J Pediatr (2015)

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

Por Cavazzuti, Antonio, Paglietti, Giuseppe, Hunter, William N., Gamarro, Francisco, Piras, Sandra, Loriga, Mario, Allecca, Sergio, Corona, Paola, McLuskey, Karen, Tulloch, Lindsay, Gibellini, Federica, Ferrari, Stefania, Costi, Maria Paola
Publicado em 2008

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

Por Schwab, Carlton L., English, Diana P., Black, Jonathan, Bellone, Stefania, Lopez, Salvatore, Cocco, Emiliano, Bonazzoli, Elena, Bussi, Beatrice, Predolini, Federica, Ferrari, Francesca, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Rutherford, Thomas, Schwartz, Peter E., Santin, Alessandro D.
Publicado no Gynecol Oncol (2015)

Dual HER2\PIK3CA targeting overcomes single-agent acquired resistance in HER2 amplified uterine serous carcinoma cell lines in vitro and in vivo

Por Lopez, Salvatore, Cocco, Emiliano, Black, Jonathan, Bellone, Stefania, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Schwab, Carlton L., English, Diana P., Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Terranova, Corrado, Angioli, Roberto, Santin, Alessandro D.
Publicado no Mol Cancer Ther (2015)

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients

Por Bellone, Stefania, Centritto, Floriana, Black, Jonathan, Schwab, Carlton, English, Diana, Cocco, Emiliano, Lopez, Salvatore, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Silasi, Dan-Arin, Ratner, Elena, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.
Publicado no Gynecol Oncol (2015)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Por Cocco, Emiliano, Lopez, Salvatore, Black, Jonathan, Bellone, Stefania, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Schwab, Carlton L, Menderes, Gulden, Zammataro, Luca, Buza, Natalia, Hui, Pei, Wong, Serena, Zhao, Siming, Bai, Yalai, Rimm, David L, Ratner, Elena, Litkouhi, Babak, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Santin, Alessandro D
Publicado no Br J Cancer (2016)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

Por Black, Jonathan D, Lopez, Salvatore, Cocco, Emiliano, Bellone, Stefania, Altwerger, Gary, Schwab, Carlton L, English, Diana P, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Santin, Alessandro D
Publicado no Br J Cancer (2015)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine serous papillary carcinoma cell lines in vitro

Por Bellone, Stefania, Black, Jonathan, English, Diana P., Schwab, Carlton L., Lopez, Salvatore, Cocco, Emiliano, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.
Publicado no Am J Obstet Gynecol (2015)